Morgan Stanley’s Anixa Biosciences ANIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.2K | Sell |
6,143
-9,365
| -60% | -$26K | ﹤0.01% | 6872 |
|
|
2026
Q1 | $40K | Sell |
15,508
-31,352
| -67% | -$92.8K | ﹤0.01% | 6502 |
|
|
2025
Q4 | $146K | Buy |
46,860
+35,191
| +302% | +$144K | ﹤0.01% | 6048 |
|
|
2025
Q3 | $38.5K | Sell |
11,669
-9,734
| -45% | -$30.8K | ﹤0.01% | 6486 |
|
|
2025
Q2 | $70.6K | Sell |
21,403
-11,922
| -36% | -$34.1K | ﹤0.01% | 6246 |
|
|
2025
Q1 | $95.3K | Buy |
33,325
+1,574
| +5% | +$4.5K | ﹤0.01% | 6033 |
|
|
2024
Q4 | $73.7K | Sell |
31,751
-150
| -0.5% | -$466 | ﹤0.01% | 6168 |
|
|
2024
Q3 | $100K | Sell |
31,901
-2,600
| -8% | -$8K | ﹤0.01% | 6009 |
|
|
2024
Q2 | $76.2K | Sell |
34,501
-2,635
| -7% | -$7.47K | ﹤0.01% | 6052 |
|
|
2024
Q1 | $116K | Sell |
37,136
-35,810
| -49% | -$143K | ﹤0.01% | 5932 |
|
|
2023
Q4 | $283K | Buy |
72,946
+36,085
| +98% | +$122K | ﹤0.01% | 5819 |
|
|
2023
Q3 | $121K | Sell |
36,861
-4,000
| -10% | -$14K | ﹤0.01% | 5795 |
|
|
2023
Q2 | $131K | Sell |
40,861
-1,954
| -5% | -$7.53K | ﹤0.01% | 5825 |
|
|
2023
Q1 | $184K | Sell |
42,815
-9,466
| -18% | -$41.4K | ﹤0.01% | 5737 |
|
|
2022
Q4 | $222K | Sell |
52,281
-8
| -0% | -$38 | ﹤0.01% | 5625 |
|
|
2022
Q3 | $257K | Sell |
52,289
-1,975
| -4% | -$8K | ﹤0.01% | 5604 |
|
|
2022
Q2 | $166K | Sell |
54,264
-12,852
| -19% | -$40.5K | ﹤0.01% | 5985 |
|
|
2022
Q1 | $184K | Buy |
67,116
+12,574
| +23% | +$36.9K | ﹤0.01% | 5971 |
|
|
2021
Q4 | $162K | Buy |
54,542
+11,329
| +26% | +$45.8K | ﹤0.01% | 6169 |
|
|
2021
Q3 | $206K | Sell |
43,213
-13,418
| -24% | -$60.5K | ﹤0.01% | 5983 |
|
|
2021
Q2 | $220K | Buy |
56,631
+47,912
| +550% | +$204K | ﹤0.01% | 5962 |
|
|
2021
Q1 | $41K | Sell |
8,719
-13,837
| -61% | -$66.1K | ﹤0.01% | 6433 |
|
|
2020
Q4 | $69K | Buy |
22,556
+8,072
| +56% | +$20.3K | ﹤0.01% | 6048 |
|
|
2020
Q3 | $35K | Sell |
14,484
-10,951
| -43% | -$28.2K | ﹤0.01% | 5847 |
|
|
2020
Q2 | $78K | Buy |
25,435
+11,023
| +76% | +$22.9K | ﹤0.01% | 5511 |
|
|
2020
Q1 | $23K | Sell |
14,412
-3,310
| -19% | -$9.7K | ﹤0.01% | 5751 |
|
|
2019
Q4 | $58K | Buy |
17,722
+4,470
| +34% | +$16.4K | ﹤0.01% | 5813 |
|
|
2019
Q3 | $53K | Sell |
13,252
-1,220
| -8% | -$5.11K | ﹤0.01% | 5702 |
|
|
2019
Q2 | $53K | Sell |
14,472
-3,281
| -18% | -$13.9K | ﹤0.01% | 5576 |
|
|
2019
Q1 | $80K | Buy |
17,753
+15,041
| +555% | +$71.7K | ﹤0.01% | 5491 |
|
|
2018
Q4 | $11K | Buy |
2,712
+1,068
| +65% | +$4.59K | ﹤0.01% | 6137 |
|
|
2018
Q3 | $7K | Sell |
1,644
-944
| -36% | -$3.55K | ﹤0.01% | 6364 |
|
|
2018
Q2 | $8K | Buy |
2,588
+705
| +37% | +$2.61K | ﹤0.01% | 6346 |
|
|
2018
Q1 | $7K | Buy |
1,883
+826
| +78% | +$3.18K | ﹤0.01% | 6332 |
|
|
2017
Q4 | $2K | Sell |
1,057
-1,955
| -65% | -$5.07K | ﹤0.01% | 6435 |
|
|
2017
Q3 | $8K | Buy |
+3,012
| New | +$3.31K | ﹤0.01% | 6207 |
|
|
2016
Q4 | – | Sell |
-5,000
| Closed | -$19K | – | 6519 |
|
|
2016
Q3 | $19K | Sell |
5,000
-5,000
| -50% | -$16.7K | ﹤0.01% | 5927 |
|
|
2016
Q2 | $31K | Sell |
10,000
-17
| -0.2% | -$52 | ﹤0.01% | 5695 |
|
|
2016
Q1 | $30K | Buy |
10,017
+2
| +0% | +$6 | ﹤0.01% | 5789 |
|
|
2015
Q4 | $30K | Buy |
10,015
+15
| +0.2% | +$53 | ﹤0.01% | 5903 |
|
|
2015
Q3 | $48K | Buy |
+10,000
| New | +$46.5K | ﹤0.01% | 5745 |
|
Other funds holding ANIX
LNWTC
DADC
GCP
Morgan Stanley's ANIX Position: Q2 2026 in Review
Morgan Stanley reduced its Anixa Biosciences (ANIX) stake by 60% in Q2 2026, selling an estimated $26K and leaving 6,143 shares worth $17.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6872.
Morgan Stanley first reported a position in ANIX in Q3 2015 and has held it in 41 quarters since. The position peaked at $283K in Q4 2023. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.
- Morgan Stanley held 6,143 shares of Anixa Biosciences worth $17.2K as of Q2 2026.
- Morgan Stanley sold 9,365 Anixa Biosciences shares in Q2 2026, an estimated $26K.
- Anixa Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6872 holding.
- Morgan Stanley first reported a position in Anixa Biosciences in Q3 2015 and has held it in 41 quarters since.
- Morgan Stanley's Anixa Biosciences position peaked at $283K in Q4 2023.
- 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.